How Family Offices Are Cracking the Code on Biotech Investing 

15 Apr

RESI Boston to Feature Global Family Office BioForum Luncheon, June 16, 2025

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) is pleased to announce the Global Family Office BioForum (GFOB) return at RESI Boston June, which will take place on Monday, June 16, 2025, at the Westin Copley Place in Boston’s Back Bay. This luncheon, held from 12:00 to 1:00 PM, brings together a curated group of family office investors focused on healthcare and life sciences.

The GFOB luncheon is part of the Redefining Every Stage of Investment (RESI) partnering conference, GFOB creates a private setting where family offices can share strategies, exchange deal flow insights, and explore potential co-investment opportunities in early-stage therapeutics. A public Family Office panel will also be held earlier in the day as part of the broader RESI agenda.

This year’s RESI Boston event will be particularly significant:

  • Over 400 life science investors and licensing partners will attend, each actively seeking new portfolio companies or co-development partners.
  • 50–75 family offices are expected to participate in the conference, creating a powerful opportunity for companies to connect directly with mission-driven capital.
  • A dedicated public Family Office panel will feature five active family office investors, each sharing how they source, vet, and evaluate early-stage biotech and medtech assets for their portfolios.

 Two Keynotes. Two Models. One Mission: Smarter Access to Biotech.

This year’s GFOB Luncheon features two complementary keynote speakers who will share actionable strategies for how family offices can participate in biotech investing without building internal venture teams or becoming scientific experts.

Chris GarabedianChris Garabedian
Founder & CEO, Xontogeny | Portfolio Manager, Perceptive Xontogeny Venture Fund

Chris Garabedian will offer a playbook for how family offices can confidently invest in early-stage therapeutics by partnering with seasoned operators. At Xontogeny, Chris has created a model that pairs hands-on operational support with strategic early capital, guiding startups from idea to clinical inflection points while minimizing founder dilution and maximizing value creation.

Backed by the Perceptive Xontogeny Venture Fund, Xontogeny supports biotech, medtech, and healthtech companies with both funding and execution—giving family offices a way to co-invest alongside industry-proven teams and access a pipeline of high-quality, professionally guided ventures.

Rick BerensonRick Berenson
Executive Committee Member, Mass Medical Angels (MA2)

Rick Berenson will present a practical approach for how family offices can assess early-stage biotech without building a whole internal diligence team. As a 15-year leader at Mass Medical Angels (MA2)—a Boston-based life science group made up entirely of industry veterans—Rick has helped refine a model that quantifies risk and potential return by leveraging the “wisdom of an expert crowd.”

He’ll explain how MA2 has used targeted micro-investments to derisk promising projects and turn them into investable biotech companies and how family offices can take advantage of this model to build a capital-efficient, scalable biotech investment pipeline.

RESI: A Smarter Way to Partner

RESI is unique because it enables matches based on stage of development and product type, making it one of the most efficient and results-driven partnering events in the life science industry. Companies come to RESI to be found. Investors and licensing partners come to source assets. The structure, scale, and precision of RESI’s partnering model make it the go-to forum for early-stage innovation and global dealmaking.

Leave a comment